Latest Amgen Stories
RnRMarketResearch.com adds “Vectibix (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
Sponsorship Secures Resources Needed for Biotech Startups to Advance Innovative Research CAMBRIDGE, Mass., Dec.
THOUSAND OAKS, Calif., Dec. 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015.
Believed to be the First Company to Have a Biosimilar Filing Accepted for Review of Amgen's Neulasta® TORONTO, Dec.
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif., Dec.
Study is the First to Evaluate Investigational Combination of an Oncolytic Immunotherapy and Anti-PD-1 Therapy THOUSAND OAKS, Calif., Dec.
This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need THOUSAND OAKS, Calif., Dec.
RnRMarketResearch.com adds Thyroid Cancer and Esophageal Cancer Pipeline Review H2 2014 to its store.
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.
- a slit in a tire to drain away surface water and improve traction.